News & Views

Thermo Reports Fourth Quarter Results

Mar 10 2017 Read 618 Times

Thermo Fisher Scientific Inc. has reported its financial results for the fourth quarter and full year ended December 31, 2016. Highlights saw fourth quarter revenue increased 6% to $4.95 billion while full year revenue increased 6% to $4.95 billion. The fourth quarter GAAP diluted earnings per share (EPS) increased 6% to $1.59; fourth quarter adjusted EPS grew 14% to $2.41. The full year GAAP diluted EPS increased 3% to $5.09 and full year adjusted EPS grew 12% to $8.27.

The company invested more than $750 million in R&D in 2016, and launched significant new products, including Q Exactive BioPharma mass spectrometry and Integrion chromatography systems, TSX laboratory freezers, Ion Torrent cancer assays, and new tests for drugs-of-abuse and autoimmune disease.

It also strengthened capabilities in Shanghai, Seoul and Singapore during the year to build on industry-leading presence in Asia-Pacific and emerging markets and continued to deliver strong growth in the region, led by outstanding performance in China.

Approximately $7 billion of capital was deployed in 2016, with $5.5 billion spent on strategic acquisitions, including FEI Company and Affymetrix and $1.5 billion was returned to shareholders through a combination of stock buybacks and dividends.

“I’m pleased to report that we achieved the goals we laid out for 2016, and successfully executed our strategy to deliver another excellent year,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific.

“We effectively deployed the largest R&D budget in our industry, and launched new high-impact products across all of our technology platforms. In Asia-Pacific and emerging markets, we leveraged our industry-leading scale to drive strong growth, especially in China, where we’re capturing opportunities aligned with the new five-year plan.

“We also continued to successfully execute our capital deployment strategy to create value for our shareholders. I’m really excited about our acquisition of FEI – the third largest in our history – and look forward to the opportunities we have to leverage these complementary technologies to drive growth.

“To sum it up, with a strong 2016 behind us, we’re positioned for another great year ahead.”

Read comments0

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Digital Edition

International Labmate Buyers Guide 2018

June 2018

In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...

View all digital editions



Jun 27 2018 Tokyo, Japan

PREP 2018

Jul 08 2018 Baltimore, MD, USA

AACC Annual Meeting & Clinical Lab Expo 2018

Jul 29 2018 Chicago, IL, USA

HPLC 2018

Jul 29 2018 Washington DC, USA

M&M 2018

Aug 05 2018 Baltimore, MD, USA

View all events